

## Thinking Of Selling Your Pharmacy?

### FREE APPRAISAL

Deal with one of the most respected Pharmacy Brokers in the industry  
A Pharmacy Broker with a comprehensive database of over 4000 registered buyers  
Australia-wide, With a reputation for honesty & Integrity;  
A Pharmacy Broker with extensive knowledge of the industry

Commission by negotiation 1800 670 440 or email [info@ravens.com.au](mailto:info@ravens.com.au)

All enquires treated with strict confidentiality

## \$20,000 Reform prize

**REFORM** Pharmacy is giving delegates to the APP conference on the Gold Coast in March this year the chance to win \$20,000 toward the cost of a new car of their own choice, by visiting the Reform Pharmacy car display stand.

See **Page 4** for details of the competition and **Page 5** for special deals available from Reform Pharmacy with "No costs, No contracts."

## FDA shares with India

**THE** US Food and Drug Administration (FDA) has said commissioner Margaret A. Hamburg will travel to India to strengthen cooperation between the organisation and Indian regulatory bodies.

Hamburg would meet with Indian policy and government leaders who deal with regulation of medical and food products exported to the US, the FDA said.

The country was the second largest provider of finished drug products, it said.

Cooperation between the countries' drug officials range from sharing information on the conduct of clinical trials to addressing product safety issues, the FDA said.

## CHF: Axe Swisse deal

**THE** Consumers Health Forum (CHF) has called for La Trobe University to axe its \$15m research deal with Swisse to form a complementary research centre.

CHF spokesman Mark Metherell said it was "fanciful" for the university to say the centre was helping consumers know more about the benefits of complementary medicines.

"As Friends of Science in Medicine state, applying rigorous research principles to the study of many Swisse products would be a waste of precious research dollars as their ingredients have already been analysed extensively and found to be of little or no benefit."

Metherell said Swisse had been ordered by a TGA complaints panel in at least 11 cases to withdraw advertising claiming products were clinically or scientifically proven, and noted the resignation of adjunct associate professor and high profile industry watchdog Dr Ken Harvey (**PD** 06 Feb).

"We hope that La Trobe recognises that its agreement with Swisse does little or nothing to contribute to its own standing or to the health of Australians."

A Swisse statement said the

centre was what the industry needed and what detractors had asked for.

In its partnership announcement, it cited economist UMR Research and Market Economics Pty Ltd with economist Stephen Koukoulas finding that complementary medicines saved the economy \$7.66b per year.

La Trobe media and communications acting director Tim Mitchell said the University had made it clear commercial partnerships would go ahead only if academic rigour and independence were at the heart of the centre and data published in peer-reviewed journals regardless of results.

He pointed to the Australian Medical Associations' statement on complementary medicine that evidence-based research was required to validate such medicines for efficacy, quality and cost effectiveness so potential benefits could be evaluated.

## Medisca TGA licenced

**PHARMACY** compounding supplier Medisca Australia has obtained its Therapeutic Goods Administration (TGA) licence to repack TGA goods.

Medisca opened its first Sydney facility in February last year, and had to demonstrate compliance with the Good Manufacturing Practice code, to ensure the product was safe for human consumption, the company said.

The TGA inspection was conducted in September and the licence was issued on 21 Jan.

Medisca Australia general manager Andrew Rowe said compounders could have confidence in products purchased from a TGA registered supplier.

## Elderberry travel

**GRIFFITH** Health Institute is running a clinical trial to determine whether elderberry capsules will protect people from colds and flus, as well as other negative health effects following long-haul flights.

Preliminary analysis of 25% of participants has shown the occurrence of cold and flu symptoms is higher in the control group, the University said.

The trial is seeking a further 180 participants to finish the study, with criteria including being over 18.

## YOUR NEW YEAR RESOLUTIONS SORTED

- INCREASE YOUR INCOME
- REDUCE YOUR COSTS
- ENGAGE YOUR CUSTOMERS AND BUILD CUSTOMER LOYALTY

 Like us on Facebook



GET YOUR ACT TOGETHER,  
CALL US NOW

**DOSE**  
innovations  
AUTOMATING PHARMACY

[www.doseinnovations.com](http://www.doseinnovations.com)

Phone: 1800 003 673 or  
Email: [enquiries@doseinnovations.com](mailto:enquiries@doseinnovations.com)



Your Pharmacy Recruitment Experts

FreeCall: 1800 429 829

Email: [info@ravensrecruitment.com.au](mailto:info@ravensrecruitment.com.au)  
Web: [www.ravensrecruitment.com.au](http://www.ravensrecruitment.com.au)

### Jobs of the Week

- **Pharmacist in Charge** - Brisbane Bayside, QLD (Job# 2010386)  
P/time Pharmacist 16.5hrs/wk with customer focused Pharmacy Group.
- **Pharmacist in Charge** - Great Ocean Road Region, VIC (Job# 2010390)  
Private Hospital needs a sole charge Pci, 3.5 hours west of Melbourne.
- **Rotational Pharmacist** - Darling Downs region, QLD (Job# 201306)  
F/time perm role - 3 pharmacies - experienced teams - great support.

Share your career vision with us and we'll help get you there!



**Don't miss the Boat.**  
Future proof your pharmacy now.  
**Get Covad.**

Call 1300 788 467 or visit us at [www.covad.com.au](http://www.covad.com.au)

covad

## LOVE IT

“I LOVE eRx Express. I am having lots of fun with it!! Have just had my 83 year old customer send me her 7 scripts from her iPhone!”

Fiona Wailes, Kofeeds Pharmacy

## Guild patient fears

**FOLLOWING** the Guild Update request for your pharmacy story (PD 04 Feb 14), Guild president David Quilty has spelled out some consequences of the early price disclosure policy in his *Forefront* editorial.

Quilty presents a case study of a pharmacist who had to let staff go, reduce local supply to a nursing home, the cost of which made the business marginal, as well as reducing services to the frail and housebound elderly.

The impact was not therefore just on the pharmacy and staff, but on the local community and even other local health suppliers such as the local ambulance and hospital which had to step into the breach in an emergency setting at the taxpayers' expense.

Read the full story by **CLICKING HERE**.

The Guild also seeks other real-life stories that demonstrate the wider impact of early price disclosure on the community: write to [natalia.webster@guild.org.au](mailto:natalia.webster@guild.org.au).

## TGA orders ad retraction

**THE** Therapeutic Goods Administration (TGA) has ordered Lifelix Pty Ltd to withdraw advertisements and publish a retraction on its websites.

The company failed to fully comply with the Complaints Resolution Panel's determination in October 2012, so the TGA delegate of the Secretary of the Department of Health reviewed the two internet advertisements.

The ads for the product, described in a copy of the advertisement included in the decision as a “natural mind and body regeneration tonic”, were found by the Delegate likely to, among other things, lead consumers to inappropriately treat potentially serious diseases.

The Delegate ordered Lifelix Pty Ltd to withdraw representations that the product was for any therapeutic use that offered benefits in relation to a list of over 50 items, including lifespan, kidneys, liver, mental clarity and bipolar conditions.

Lifelixer was also ordered to display a retraction on its website for 90 days, which read in part that the company had provided no evidence to support the claims made, and that the Panel found the claims “unlawful, misleading and unverified.”

Lifelixer has 10 working days to provide evidence of compliance and a written response that it will continue to abide by the TGA order.

A response from the Advertiser had not yet been received by the TGA, however the advertising subject of the complaint had been withdrawn, a TGA spokesperson said.

Lifelixer representative Karen Phillips said the company would be complying with TGA instructions to remove the site and had been trying for several weeks, but had had issues with its web host.

The company was disappointed with the course of the process, she said, and felt the TGA should insist on complainants being identified.

## CVS Caremark quits

**US** giant CVS Caremark chain of pharmacies will stop selling tobacco products as of 01 Oct.

Ceo Larry Merlo said tobacco products had no place in a setting where healthcare was delivered, the *BBC* reported.

Merlo said this would cost the company of 7,600 stores and 26,000 pharmacists and nurse practitioners US\$2b, the publication reported.

The chain made US\$125b in sales last year, the *BBC* said.

TobaccofreeRX, an interdisciplinary group of healthcare professionals, called on Walgreens and Rite Aid to join CVS in ending the sale of tobacco products in their pharmacies.

**MEANWHILE** the FDA has launched its first national public education campaign to prevent, youth tobacco use and reduce the number of 12 to 17 year olds who become regular smokers.

The first of several campaigns, “The Real Cost” targeted the 10m young people who have never smoked but are open to it.

## January MIMS Monthly Medicine Update

### NEW PRODUCTS

**Bexsero (multicomponent meningococcal group B vaccine (recombinant, adsorbed))** is indicated in the active immunisation against invasive disease caused by *Neisseria meningitidis* group B strains in individuals ≥ 2 months. Bexsero is available as a 0.5 mL suspension for injection in a prefilled syringe in packs of 1's.

**Cinryze (human C1 esterase inhibitor)** is a member of the serine protease inhibitor, or serpin, superfamily of proteins. C1 esterase inhibitor inhibits the complement system by binding C1r and C1s, two of the active enzyme subunits of the first component of the complement system (C1) in the classical pathway, as well as to mannose-binding lectin-associated serine proteases in the lectin pathway. Cinryze is indicated in the treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with C1 inhibitor deficiency; and routine prevention in adults and adolescents with frequent attacks of hereditary angioedema intolerant to or insufficiently protected by oral therapy. Cinryze is available as a 500 unit powder for injection in packs of 2's.

**Giotrif (afatinib (as afatinib dimaleate))** is an irreversible ErbB family blocker. Afatinib covalently binds to and irreversibly blocks signalling from all homo- and heterodimers formed by the ErbB family members EGFR (epidermal growth factor receptor, ErbB1), HER2 (human epidermal growth factor receptor 2, ErbB2), ErbB3 and ErbB4. It is indicated in monotherapy for treatment (1st line or after cytotoxic chemotherapy failure) of advanced or metastatic non-squamous non-small cell

carcinoma of the lung (tumours must have EGFR exon 19 deletions or L858R substitution mutations). Giotrif is available as 20, 30, 40 and 50 mg tablets in packs of 28's.

**Gliolan (aminolevulinic acid hydrochloride)** is a natural biochemical precursor of heme that is metabolised in a series of enzymatic reactions to fluorescent porphyrins, particularly PPIX. In the presence of visible light, fluorescence of PPIX (photodynamic effect) in certain target tissues can be used for photodynamic diagnosis. Gliolan is indicated in malignant tissue visualisation during malignant glioma surgery in adults (intended tumour resection and glioblastoma multiforme on preoperative imaging). Gliolan is contraindicated in patients with porphyrin hypersensitivity; acute, chronic porphyria and is also contraindicated in pregnancy. Gliolan is available as a 1.5 g powder for oral solution in single vials.

**Intragam 10 NF (normal human immunoglobulin)** is indicated for replacement IgG therapy in primary immunodeficiency disease (PID), symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment; immunomodulation for idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), myasthenia gravis (MG) (in myasthenic crisis or prior to surgery, thymectomy; maintenance for moderate to severe MG when other treatments ineffective or intolerable), nonparaneoplastic Lambert-Eaton myasthenic syndrome (LEMS) (short-term use in severely affected patients) and in stiff person syndrome. Intragam 10 NF is available as a 2.5 g/25 mL, 5 g/50 mL, 10 g/100 mL and 20 g/200 mL solution for infusion in single use vials.

**Load 375 (copper)** is an intrauterine device (IUD) with 375 cm<sup>2</sup> copper surface area, suitable for uterine cavities with a depth of 7 cm or more. The contraceptive action of the IUD is essentially provided by the spermicidal action of copper ions. After oxidation, the copper ions diffuse locally at the level of the cervical mucus and of the endometrium. It is indicated as contraception including emergency contraception. It is contraindicated in the following conditions. Absolute contraindications: uterine abnormality, malformation, disorder; salpingitis; endometriosis; suspected neoplasia; tumour; fibroma; polyp; recent pelvic inflammation; undiagnosed genital bleeding; Wilson's disease; high frequency radiotherapy or electrotherapy (including microwave, diathermy) to lower pelvic region; and pregnancy. Relative contraindications: uterine scarring not caused by caesarean; dysmenorrhoea and menorrhagia. Load 375 IUD is available in packs of 1's.

**Nesina Met (alogliptin/ metformin hydrochloride)** contains two oral antihyperglycaemic drugs: alogliptin (as benzoate), a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class. Nesina Met is indicated as an adjunct to diet and exercise to improve glycaemic control in type 2 diabetes: patients inadequately controlled with metformin alone; patients currently treated with alogliptin + metformin combination (separate tablets; fixed dose combination not for initial treatment) and as a combination with thiazolidinedione (TZD) or insulin (inadequately controlled by dual therapy). It is contraindicated in the following conditions. Renal disease or dysfunction (serum creatinine ≥ 135 micromol/L (males), ≥ 110 micromol/L

(females), CrCl less than 60 mL/min) including those caused by CV collapse (shock), acute MI, septicemia; acute or chronic metabolic acidosis including diabetic ketoacidosis, diabetic coma, pre-coma; radiological studies involving intravascular iodinated contrast material administration (temporarily discontinue prior to or at time of procedure; withhold for 48 hrs post-procedure, may reintroduce if renal function normal). Nesina Met is available in packs of 56's as alogliptin (as benzoate)/metformin hydrochloride 12.5 mg/500 mg, 12.5 mg/850 mg and 12.5 mg/1000 mg.

**Signifor (pasireotide diaspertate)** is a cyclohexapeptide, injectable somatostatin analogue. Like natural peptide hormones somatostatin-14 and somatostatin-28 and other somatostatin analogues, pasireotide exerts its pharmacological activity via binding to somatostatin receptors. Five human somatostatin receptor subtypes are known: hsst 1, 2, 3, 4, and 5. These receptor subtypes are expressed in different tissues under normal physiological conditions. Due to its broad affinity profile to somatostatin receptors (high affinity binding to receptor subtypes 1, 2, 3 and 5), pasireotide has the potential to treat diseases characterized by expression of those receptors in the target tissues. Signifor is indicated in adults with Cushing's disease where surgery is unsuitable or has failed. It is contraindicated in severe hepatic impairment (Child-Pugh C). Signifor is available as a solution for injection containing 300 mcg/mL, 600 mcg/mL and 900 mcg/mL in 1 mL glass ampoules in packs of 60's.

**TT380 (copper)** standard is an IUD with 380 cm<sup>2</sup> copper surface area, suitable for uterine cavities with a depth of 7 cm or more.

**TT380 (copper)** short is an intrauterine device suitable for uterine cavities with a depth less than 7 cm. The contraceptive action of the IUD is essentially provided by the spermicidal action of copper ions. After oxidation, the copper ions diffuse locally at the level of the cervical mucus and of the endometrium. It is indicated in contraception including emergency contraception. TT380 is contraindicated in the following conditions. Absolute contraindications: uterine abnormality, malformation, disorder; salpingitis; endometriosis; suspected neoplasia; tumour; fibroma; polyp; recent pelvic inflammation; undiagnosed genital bleeding; Wilson's disease; high frequency radiotherapy or electrotherapy (including microwave, diathermy) to lower pelvic region; and pregnancy. Relative contraindications: uterine scarring not caused by caesarean; dysmenorrhoea and menorrhagia. TT380 standard and TT380 short IUDs are available in packs of 1's.

### NEW INDICATIONS

**Galvus (vildagliptin)** is now indicated in combination with insulin (with or without metformin) when diet, exercise and a stable dose of insulin do not result in adequate glycaemic control.

### SAFETY RELATED CHANGES

**Valdoxan (agomelatine)** is now contraindicated in patients with hepatic transaminases exceeding 3 times the upper limit of normal.

*This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.*





- Cost Effective
- Targeted
- Easy

## Events Calendar

**WELCOME** to *Pharmacy Daily's* events calendar, opportunities to earn CPE and CPD points.

If you have an upcoming event you'd like us to feature, email [info@pharmacydaily.com.au](mailto:info@pharmacydaily.com.au).

**8 Feb:** Pharmacy on the Move; Sydney; more info at: [www.psa.org.au](http://www.psa.org.au)

**21-23 Feb:** CPD by the SEA - NSW Convention; Novotel Sydney Manly Pacific [www.cpdbythesea.com.au](http://www.cpdbythesea.com.au)

**21-23 Feb:** Foundation Clinical Pharmacy Practice Seminar; InterContinental Adelaide - see more at: [www.shpa.org.au](http://www.shpa.org.au)

**23 Feb:** Complementary Medicines: an evidence-guided approach; Melbourne, [www.pharmeducation.com.au](http://www.pharmeducation.com.au)

**28 Feb - 1 Mar:** Blackmores Institute Symposium; Australian Technology Park, Sydney, more info at: <http://wired.ivvy.com/event/BIS13/>

**1-2 Mar:** Cardiology Seminar; Sofitel Gold Coast Broadbeach - visit: [www.shpa.org.au](http://www.shpa.org.au)

**7-9 March:** PSA Annual Therapeutic Update; Crown Plaza Terrigal; see [www.psa.org.au/conferences](http://www.psa.org.au/conferences)

**13-16 Mar:** Pharmacy Guild of Australia Annual National Conference APP 2014, Gold Coast - see [www.appconference.com](http://www.appconference.com)

**22-23 Mar:** The Goodfellow Symposium, Auckland - see [www.goodfellowsymposium.org](http://www.goodfellowsymposium.org)

**11-12 Apr:** 2nd BioCeuticals Research Symposium; Sofitel Sydney Wentworth; see: [www.bioceuticals.com.au](http://www.bioceuticals.com.au)

**12-14 Apr:** FIP Fifth Pharmaceutical Sciences World Congress, Melbourne - for details **CLICK HERE**.

## New sterile Phebra plant

**AUSTRALIAN** pharmaceutical firm Phebra has announced that manufacturing and product supply from its new sterile manufacturing plant at Lane Cove West has commenced.

Phebra is a specialty pharmaceutical company that develops, manufactures and markets medicines in Australia, New Zealand, Asia, Canada and parts of Europe.

The company's products cover a range of pharmaceuticals in disease areas such as cystic fibrosis, antidotes, diagnostics, oncology and pain.

Phebra ceo Dr Mal Eutick, said the company had relocated from its previous site at Burns Bay Road, Lane Cove, which has now been closed and the site sold for the development of a significant number of residential units.

Eutick said the new plant, situated at Orion Road, allowed Phebra to greatly enhance its current manufacturing capacity for the local Australian and New Zealand markets and wider export markets.

"The facility will deliver extra production capacity for Phebra to manufacture our wide range of critical medicines, as well as expanding our capability to conduct all-important development programs now and into the future," he added.

## Gamifying medicine

**HOSPITALS** and big pharma are using gamification on mobile devices to engage healthcare professionals and patients.

For example Pfizer has developed a video game called *Evo Challenge* which elderly people can use to establish a baseline level of cognitive ability and measure the progressive impact of dementia.

Other gamification relates to education of resident doctors using mobile devices to sharpen their knowledge of the latest research and compare themselves with their colleagues while behind the scenes, supervisors can monitor results.

Boehringer Ingelheim is also using this approach.

## DISPENSARY CORNER

**WE** are So(CHI) ready.

The Sochi Winter Olympics might be a good example of the power of social media; an entire Twitter account has been set up detailing the woes of Russia's efforts to get ready.

@SochiProblems has 29,000 followers and tweets photos of doorknobs breaking off doors, two toilets in one stall, brown hotel tap water and a hallway with several power cords running through it with the caption "Hallways very dangerous, keep calm and carry on..or trip and fall and hit head."

The account's descriptor is "I'm a mess, and not prepared for you!"

**HOLY** Harley!

If you were wanting to do something good while bagging a Harley-Davidson donated to Pope Francis, too late - the bike, with a fuel tank signed by the Pontiff, has sold for more than \$360,000 to a private buyer in Europe, with the money to be donated to Rome-based homeless charity Caritas, the *Guardian* reported.

Donated by retired Harley designer and grandson of the co-founder, Willie Davidson, it's not known whether the Pope ever took a spin on the bike, the *Associated Press* reported.

**LET'S** not skirt the issue.

Ever chafed at a work dress code?

You could take a leaf out of Andrew Amaral Silva's book, whose work banned wearing shorts to work.

With temperatures reaching over 40 degrees and broken air conditioning at work, Silva decided to wear his wife's long black skirt to work, the *South African Press Association* (SAPA) reported.

The story went viral and Silva has told media he's thinking of keeping the skirt due to its comfort, the SAPA reported.

## WIN A derma e PACK

Every day this week **Pharmacy Daily** is giving one lucky reader the chance to win a **derma e** pack, valued at \$43.90 each.

Known as the "Skin Vitamin", Vitamin E is peerless at rehydrating and nourishing even the driest, most severely cracked skin. derma e<sup>®</sup> uses potent amounts of high quality Vitamin E in its Vitamin E Moisturising Crème and Skin Oil. The Skin Oil is fantastic for scars, stretch marks and ageing skin. Both products can be used on the face and body.

To win this great prize pack, simply be the first person to send through the correct answer to the question below.



derma e<sup>®</sup>  
natural skincare  
solutions that work

Is derma e<sup>®</sup> tested on animals?

Send your answer to: [comp@pharmacydaily.com.au](mailto:comp@pharmacydaily.com.au)

Congratulations to yesterday's lucky winner, **Michael Byrne** from **Corum Health Services**.





# WIN \$20,000 towards a car of your choice AT APP2014!

**Reform Pharmacy** is giving APP delegates the chance to win \$20,000 to put towards a car of choice from the following range:



**To enter simply visit the Reform Pharmacy Car Display stand at APP and answer some simple questions.**

The competition opens at 8.30am Friday 14 March and closes at 5.00pm Saturday 15 March.  
The winner will be announced at the APP Gala Dinner on Saturday evening.

To view the competition terms and conditions please visit:  
[www.reformmanagement.com.au/APPConference2014](http://www.reformmanagement.com.au/APPConference2014) or [www.appconference.com](http://www.appconference.com)

**WITH THE STRENGTH OF OVER  
1,000 PHARMACIES NATIONALLY  
JOIN US TODAY “IT’S FREE”**

<b>Product Name</b>	<b>Min QTY</b>	<b>Net into Store "each"</b>
Spree 1L Dishwashing Liquid Frangipani / Lemon	12	\$ 1.19
AJAX 500mL SPRAY (Orange Blossom, Window, Lavender & Citrus, Ocean Fresh)	8	\$ 1.69
REXONA 100g DEODORANT WOMEN CRYSTAL CLEAR AQUA BODY SPRAY	12	\$ 1.59
Rexona Men and Women Roll On 40ml (assorted fragrances)	6	\$ 1.25
LYNX 100g BODY SPRAY - (assorted fragrances)	6	\$ 2.99
Dove 100g Soaps (various types)	6	\$ 0.80
INDULGE 170mL NAIL POLISH REMOVER ACETONE	6	\$ 0.99
COLGATE TOOTHBRUSH EXTRA CLEAN MEDIUM & SOFT	12	\$ 0.55
COLGATE TWIN PACK TOOTHBRUSHES EXTRA CLEAN MEDIUM (2 PACK)	12	\$ 0.95
COLGATE 80g TOOTHPASTE FRESH CONFIDENCE GEL	12	\$ 0.55
SUNSILK 200mL SHAMPOO (various types)	12	\$ 1.45
SUNSILK 200mL CONDITIONER (various types)	12	\$ 1.45
PALMOLIVE 400mL KIDS 2 in 1 SHAMPOO & CONDITIONER HAPPY APPLE	12	\$ 0.99
VO5 75mL HAIR MOULD THE FUNKY SHAPER EXTREME	6	\$ 1.40
VO5 150mL HAIR MATTE EFFECT TEXTURISING PASTE SURF STYLE	6	\$ 1.40
VO5 30g EXTREME STYLE REWORK FIBRE PUTTY *Buy in units of 6*	6	\$ 1.40
SPREE 500g LAUNDRY POWDER ULTRA APPLE FRESH	12	\$ 1.19
DUO 1kg LAUNDRY POWDER ULTRA CONCENTRATE FRONT LOADER	6	\$ 1.59
VANISH 500g NAPISAN OXI ACTION INWASH FABRIC STAIN REMOVER	12	\$ 2.15
SARD 500mL OXY PLUS - various types	8	\$ 1.75
WHITE KING 750mL BLEACH PREMIUM LAVENDER	6	\$ 1.15
FLUFFY 250mL FABRIC CONDITIONER REFILL (various fragrances)	12	\$ 1.05
CUDDLY 300mL FABRIC CONDITIONER REFILL (various fragrances)	12	\$ 1.05
CUDDLY 1L FABRIC CONDITIONER READY TO USE (various fragrances)	12	\$ 2.19

**Reform Management Pty Ltd (ABN 52 150 882 376) Unit 1, 21 Rodeo Road. NSW 2557**

**On sale only while stocks last \* All pricing is exclusive of GST.**

**REFORM PHARMACY, NO COST, NO CONTRACTS**

**[www.reformmanagement.com.au](http://www.reformmanagement.com.au)**